Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01742065 · ClinicalTrials.gov registry record · NA
Strategies and Opportunities to Stop Colon Cancer in Priority Populations
A NA study, sponsored by Kaiser Permanente.
- Completed
- Registry status
- NA
- Development phase
- 62,155
- Enrollment target
NCT01742065 is a NA study that has completed, run by Kaiser Permanente. The registered enrollment target is 62,155 participants.
The verdict
NCT01742065, a NA study, has completed, sponsored by Kaiser Permanente.
- COMPLETED
- Registry status
- NA
- Development phase
- 62,155 participants
- Enrollment target
Study Summary
Only an estimated 50 million US adults aged 50-75 are up-to-date on colorectal cancer (CRC) screening according to guidelines set by the federal government. CRC is 90% curable with timely detection and appropriate treatment of precancerous polyps; increased screening could reduce incidence by up to 50%. Groups least likely to undergo screening, those with minimal education, low income, low access to health care, recent immigrants or Hispanics, are the same people who frequently receive care at Federally Qualified Healthcare Center's (FQHCs). The use of fecal occult blood tests (FOBT) and fecal immunochemical tests (FIT) is exceedingly low in FQHCs (7-9% of patients in the past year) and far below national averages and target rates. Our results will provide valuable information on how to use electronic health record (EHR) resources to optimize guideline-based screening in FQHC clinics whose patient populations have disproportionately low CRC screening rates. This project, in conjunction with the research team, will use an advisory panel to direct the research activities. The advisory panel will be made up of clinicians, leaders, researchers, and patients. The panel and team will guide the development of materials, the outreach to patients, and the research protocol to best reach FQHC patients who are due for colorectal cancer screening. This project will be conducted in two phases, Phase I is conducting a pilot at two FQHC's, and Phase II is rolling out the intervention to between 20-30 clinics.
Interventions
- OTHER Auto Plus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62,155 participants |
| Start Date | 2013-01 |
| Est. Completion | 2018-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01742065
The ClinicalTrials.gov registry entry for NCT01742065 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 62,155 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kaiser Permanente, which has 294 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Auto Plus is the first listed.
NCT01742065 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01742065 about?
NCT01742065 is a clinical study titled "Strategies and Opportunities to Stop Colon Cancer in Priority Populations". Only an estimated 50 million US adults aged 50-75 are up-to-date on colorectal cancer (CRC) screening according to guidelines set by the federal government. CRC is 90% curable with timely detection and appropriate treatment of precancerous polyps; increased screening could reduce incidence by up to ...
What is the current status of trial NCT01742065?
This trial is currently completed. It is a NA study. The enrollment target is 62,155 participants. The study started on 2013-01. Estimated completion is 2018-08.
What interventions are being tested in trial NCT01742065?
The interventions under investigation include: Auto Plus (OTHER).
Who is sponsoring clinical trial NCT01742065?
This trial is sponsored by Kaiser Permanente, which has 294 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.